Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1987 1
1988 1
1989 3
1990 3
1991 3
1992 1
1993 2
1994 4
1995 4
1996 3
1997 1
1998 1
1999 4
2000 1
2002 5
2003 6
2005 2
2006 1
2007 2
2008 15
2009 14
2010 6
2011 9
2012 13
2013 7
2014 11
2015 9
2016 17
2017 10
2018 19
2019 29
2020 17
2021 32
2022 26
2023 32
2024 9
2025 21

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

304 results

Results by year

Filters applied: . Clear all
Page 1
Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial.
Nassiri F, Patil V, Yefet LS, Singh O, Liu J, Dang RMA, Yamaguchi TN, Daras M, Cloughesy TF, Colman H, Kumthekar PU, Chen CC, Aiken R, Groves MD, Ong SS, Ramakrishna R, Vogelbaum MA, Khagi S, Kaley T, Melear JM, Peereboom DM, Rodriguez A, Yankelevich M, Nair SG, Puduvalli VK, Aldape K, Gao A, López-Janeiro Á, de Andrea CE, Alonso MM, Boutros P, Robbins J, Mason WP, Sonabend AM, Stupp R, Fueyo J, Gomez-Manzano C, Lang FF, Zadeh G. Nassiri F, et al. Nat Med. 2023 Jun;29(6):1370-1378. doi: 10.1038/s41591-023-02347-y. Epub 2023 May 15. Nat Med. 2023. PMID: 37188783 Free PMC article. Clinical Trial.
Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies.
Leclercq-Cohen G, Steinhoff N, Albertí Servera L, Nassiri S, Danilin S, Piccione E, Yángüez E, Hüsser T, Herter S, Schmeing S, Gerber P, Schwalie P, Sam J, Briner S, Jenni S, Bianchi R, Biehl M, Cremasco F, Apostolopoulou K, Haegel H, Klein C, Umaña P, Bacac M. Leclercq-Cohen G, et al. Clin Cancer Res. 2023 Nov 1;29(21):4449-4463. doi: 10.1158/1078-0432.CCR-22-3667. Clin Cancer Res. 2023. PMID: 37379429 Free PMC article.
See related commentary by Luri-Rey et al., p. 4320....
See related commentary by Luri-Rey et al., p. 4320....
Chromosome 1p Loss and 1q Gain for Grading of Meningioma.
Landry AP, Wang JZ, Patil V, Liu J, Gui C, Ellenbogen Y, Ajisebutu A, Yefet L, Wei Q, Singh O, Sosa J, Mansouri S, Cohen-Gadol AA, Tabatabai G, Tatagiba M, Behling F, Barnholtz-Sloan JS, Sloan AE, Chotai S, Chambless LB, Mansouri A, Makarenko S, Yip S, Ehret F, Capper D, Tsang DS, Moliterno J, Gunel M, Wesseling P, Sahm F, Aldape K, Gao A, Zadeh G, Nassiri F. Landry AP, et al. JAMA Oncol. 2025 Jun 1;11(6):644-649. doi: 10.1001/jamaoncol.2025.0329. JAMA Oncol. 2025. PMID: 40178835 Free PMC article.
RESULTS: Among 1964 patients with meningioma (1256 female; median [IQR] age, 58 [48-69] years) assessed, loss of chromosome 1p in WHO grade 1 meningiomas was associated with significantly worse outcomes compared with tumors without loss of 1p (median PFS, 5.83 [95% CI, 4.36-] yea …
RESULTS: Among 1964 patients with meningioma (1256 female; median [IQR] age, 58 [48-69] years) assessed, loss of chromosome 1p in WHO grade …
International Tuberculum Sellae Meningioma Study: Surgical Outcomes and Management Trends.
Magill ST, Schwartz TH, Couldwell WT, Gardner PA, Heilman CB, Sen C, Akagami R, Cappabianca P, Prevedello DM, McDermott MW; International Tuberculum Sellae Meningioma Study Authors. Magill ST, et al. Neurosurgery. 2023 Dec 1;93(6):1259-1270. doi: 10.1227/neu.0000000000002569. Epub 2023 Jun 30. Neurosurgery. 2023. PMID: 37389475 Free PMC article.

GTR decreased with increased diameter (OR: 0.80 per cm, P = .0036) and preoperative visual deficits (OR 0.56, P = .0075). Mortality was 0.5%. ...The cerebrospinal fluid leak rate was 17.3% for EEA and 2.2% for TCA (OR 9.1, P < .0001). The recurrence rate w

…
GTR decreased with increased diameter (OR: 0.80 per cm, P = .0036) and preoperative visual deficits (OR 0.56, P = .0075). Mort …
Distinct immune cell infiltration patterns in pancreatic ductal adenocarcinoma (PDAC) exhibit divergent immune cell selection and immunosuppressive mechanisms.
Sivakumar S, Jainarayanan A, Arbe-Barnes E, Sharma PK, Leathlobhair MN, Amin S, Reiss DJ, Heij L, Hegde S, Magen A, Tucci F, Sun B, Wu S, Anand NM, Slawinski H, Revale S, Nassiri I, Webber J, Hoeltzel GD, Frampton AE, Wiltberger G, Neumann U, Charlton P, Spiers L, Elliott T, Wang M, Couto S, Lila T, Sivakumar PV, Ratushny AV, Middleton MR, Peppa D, Fairfax B, Merad M, Dustin ML, Abu-Shah E, Bashford-Rogers R. Sivakumar S, et al. Nat Commun. 2025 Feb 6;16(1):1397. doi: 10.1038/s41467-024-55424-2. Nat Commun. 2025. PMID: 39915477 Free PMC article.
IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma.
Taylor CA, Watson RA, Tong O, Ye W, Nassiri I, Gilchrist JJ, de Los Aires AV, Sharma PK, Koturan S, Cooper RA, Woodcock VK, Jungkurth E, Shine B, Coupe N, Payne MJ, Church DN, Naranbhai V, Groha S, Emery P, Mankia K, Freedman ML, Choueiri TK, Middleton MR, Gusev A, Fairfax BP. Taylor CA, et al. Nat Med. 2022 Dec;28(12):2592-2600. doi: 10.1038/s41591-022-02095-5. Epub 2022 Dec 16. Nat Med. 2022. PMID: 36526722 Free PMC article.
Consensual Ophthalmotonic Reaction Following Selective Laser Trabeculoplasty.
Nassiri N, Mei F, Tokko H, Zeiter J, Syeda S, Kim C, Swendris R, Goyal A, Veld EI, Mas-Ramirez A, Rana SW, Juzych MS, Hughes BA. Nassiri N, et al. J Curr Glaucoma Pract. 2022 Jan-Apr;16(1):36-40. doi: 10.5005/jp-journals-10078-1361. J Curr Glaucoma Pract. 2022. PMID: 36060042 Free PMC article.
RESULTS: At all follow-up periods, the IOP of the treated eye was decreased from baseline IOP (p 0.05, paired t-test). For the fellow eye, there was a statistically significantly decrease from baseline up to the 4-9 months follow-up period (p 0.05, paired t-test). L …
RESULTS: At all follow-up periods, the IOP of the treated eye was decreased from baseline IOP (p 0.05, paired t-test). For the fellow …
Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.
Suppiah S, Mansouri S, Mamatjan Y, Liu JC, Bhunia MM, Patil V, Rath P, Mehani B, Heir P, Bunda S, Velez-Reyes GL, Singh O, Ijad N, Pirouzmand N, Dalcourt T, Meng Y, Karimi S, Wei Q, Nassiri F, Pugh TJ, Bader GD, Aldape KD, Largaespada DA, Zadeh G. Suppiah S, et al. Nat Commun. 2023 May 10;14(1):2696. doi: 10.1038/s41467-023-38432-6. Nat Commun. 2023. PMID: 37164978 Free PMC article.
CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade.
Milotay G, Little M, Watson RA, Muldoon D, MacKay S, Kurioka A, Tong O, Taylor CA, Nassiri I, Webb LM, Akin-Adigun O, Bremke J, Ye W, Sun B, Sharma PK, Cooper R, Danielli S, Santo FM, Verge de Los Aires A, Niu G, Cohen L, Ng E, Gilchrist JJ, Chong AY, Mentzer A, Woodcock V, Coupe N, Payne MJ, Youdell M, Middleton MR, Klenerman P, Fairfax BP. Milotay G, et al. Nat Med. 2025 Jul;31(7):2350-2364. doi: 10.1038/s41591-025-03647-1. Epub 2025 Apr 23. Nat Med. 2025. PMID: 40269332 Free PMC article.
We identify TBX21, encoding T-bet, as a transcriptional driver of CMV-associated CD8(+) T cell gene expression, finding that TBX21 expression is predictive of overall survival (hazard ratio: 0.62, P = 0.026). CMV(+) patients unexpectedly show reduced cumulative incidence o …
We identify TBX21, encoding T-bet, as a transcriptional driver of CMV-associated CD8(+) T cell gene expression, finding that TBX21 expressio …
304 results